Walter Alexander | Authors


1901 1ST AVE


Ofatumumab generates high response rates in refractory CLL

December 10, 2010

Ofatumumab (Arzerra) demonstrated clinical benefit was superior to historic outcomes with salvage therapies in this setting, according to lead investigator William G. Wierda, MD, PhD. After about 26 months of median follow-up, progression-free survival and overall survival improved in fludarabine-refractory chronic lymphocytic leukemia and in fludarabine-refractory CLL with bulky lymph nodes.

Deeper Molecular Responses Seen with Dasatinib in New Chronic Myeloid Leukemia

December 07, 2010

The median reductions in Bcr-Abl transcripts at one year were greater with dasatinib (Sprycel) than with imatinib (Gleevec), according to the results of an intergroup phase II trial. A better molecular response should eventually correlate with better outcomes, making dasatinib a serious contender for upfront therapy in CML.

Letrozole appears less detrimental than tamoxifen to cognitive function in breast ca

July 28, 2009

Research by the International Breast Cancer Study Group furthers knowledge on how anti-estrogen agents affect cognitive function and memory.